




The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. This is the fastest way to end the pandemic. So we want to know: **do world leaders' actions move us closer to, or further from, an equitable outcome?** The Vaccine Access Test provides a framework to answer this question based on the following metrics:

- **Support for & Collaboration with ACT-A:** Has this company collaborated with or provided financial support?
- **Transparency & Knowledge Sharing:** Has the company committed to non-profit and/or tiered pricing? Does this company share relevant knowledge and data to enable widespread access?
- **Multilateral Leadership:** Has leadership expended political capital to motivate cooperation on equity?
- **Deals:** Each deal this company has made to secure promising COVID-19 vaccine candidates is scored individually based on a set of metrics for how well they advance equity.

Each metric is worth up to 3 points and Deal Scores can earn up to 6 points. **BioNTech can earn up to 15 points.**

METRIC	SCORE	RATIONALE
<b>ACT-A</b> 	1	BioNTech has signed up to the Gavi COVAX AMC and committed 40m vaccine doses
<b>Transparency &amp; Knowledge Sharing</b> 	0	BioNTech has not committed to non-profit and/or tiered pricing and has committed to sharing knowledge <i>only</i> within its partnership with Pfizer.
<b>Multilateral Leadership</b> 	0	BioNTech executives have mentioned the need for global equity but have not used political capital to advance equity globally.
<b>Deal Score (average)</b>	1.3	BioNTech has completed 6 deals with countries, with an average Deal Score of 1.3.

## Total Score: 2.3 out of 15

BioNTech's actions so far have not demonstrated dedication to equitable outcomes and advancing equity.

BioNTech can improve their score by supporting ACT-A financially and by sharing relevant knowledge, intellectual property and data to enable wide scale production, distribution and use of vaccines, as outlined in the WHO's Solidarity Call to Action.

